¹H NMR-based metabolic profiling of human rectal cancer tissue

Abstract

BackgroundRectal cancer is one of the most prevalent tumor types. Understanding the metabolic profile of rectal cancer is important for developing therapeutic approaches and molecular diagnosis.MethodsHere, we report a metabonomics profiling of tissue samples on a large cohort of human rectal cancer subjects (n = 127) and normal controls (n = 43) using 1H nuclear magnetic resonance (1H NMR) based metabonomics assay, which is a highly sensitive and non-destructive method for the biomarker identification in biological systems. Principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal projection to latent structure with discriminant analysis (OPLS-DA) were applied to analyze the 1H-NMR profiling data to identify the distinguishing metabolites of rectal cancer.ResultsExcellent separation was obtained and distinguishing metabolites were observed among the different stages of rectal cancer tissues (stage I = 35; stage II = 37; stage III = 37 and stage IV = 18) and normal controls. A total of 38 differential metabolites were identified, 16 of which were closely correlated with the stage of rectal cancer. The up-regulation of 10 metabolites, including lactate, threonine, acetate, glutathione, uracil, succinate, serine, formate, lysine and tyrosine, were detected in the cancer tissues. On the other hand, 6 metabolites, including myo-inositol, taurine, phosphocreatine, creatine, betaine and dimethylglycine were decreased in cancer tissues. These modified metabolites revealed disturbance of energy, amino acids, ketone body and choline metabolism, which may be correlated with the progression of human rectal cancer.ConclusionOur findings firstly identify the distinguishing metabolites in different stages of rectal cancer tissues, indicating possibility of the attribution of metabolites disturbance to the progression of rectal cancer. The altered metabolites may be as potential biomarkers, which would provide a promising molecular diagnostic approach for clinical diagnosis of human rectal cancer. The role and underlying mechanism of metabolites in rectal cancer progression are worth being further investigated.

Nuclear magnetic resonance-based study reveals the metabolomics profile of nasopharyngeal carcinoma

“…The standard one-dimension spectrum gave an overview of all metabolites. The major metabolites in the spectra were identified according to literature data and the Human Metabolome Database (http://www.hmdb.ca/) (Wang et al, 2013). As a result, a series of differential metabolite levels were observed in the plasma from NPC patients in comparison with healthy controls.…”

Metabonomics studies on serum and urine of patients with breast cancer using 1H-NMR spectroscopy

“…Metabonomics can provide complementary information that cannot be obtained directly from the genotype, geneexpression profiles, or even the proteome of an organism [4]. In addition, it can identify early signals/biomarkers of cellular abnormalities that occur before the changes of gross phenotype [5]. Currently, metabolomics has been widely used in biomarker detection, disease diagnosis and evaluation of treatment and prognosis [6].…”

The promise of metabolic phenotyping in gastroenterology and hepatology

“…88 Other NMRbased studies have identified elevated lactate, threonine, serine, acetate, succinate, formate and tyrosine levels with lower concentrations of taurine, creatine, betaine and myoinositol in tumour tissue compared with adjacent nonmalignant tissue. 89 In terms of biofluids, studies using GC-MS, NMR, LC-MS, capillary electrophoresis-mass spectrometry (CE-MS) and MALDI-MS, all report consistent differences between biological samples from healthy individuals and patients with cancer. Numerous metabolic profiling studies have found differences in the serum of patients with CRC in comparison with healthy individuals and, in some incidences, patients with polyps.…”